Sodium glucose transporter protein 2 inhibitors: focusing on the kidney to treat type 2 diabetes
Therapeutic Advances in Endocrinology and Metabolism, 2014 Type 2 diabetes mellitus (T2DM) is increasing worldwide. Treatment of T2DM continues to present challenges, with a significant proportion of patients failing to achieve and maintain glycemic targets.
Bernard Peene, Katrien Benhalima
doaj +1 more source
Sodium-Glucose Cotransporter 2 Inhibitors as Emerging Anticancer Agents [PDF]
Diabetes & Metabolism JournalSodium-glucose cotransporter 2 (SGLT2) inhibitors are established treatments for type 2 diabetes mellitus, heart failure, and chronic kidney disease, with well-documented metabolic and cardiorenal benefits.
Yun Kyung Cho, Chang Hee Jung
doaj +1 more source
Update on developments with SGLT2 inhibitors in the management of type 2 diabetes
Drug Design, Development and Therapy, 2014 Michael A Nauck Department of Internal Medicine, Diabeteszentrum Bad Lauterberg, Bad Lauterberg im Harz, Germany Abstract: The importance of the kidney's role in glucose homeostasis has gained wider understanding in recent years.
Nauck MA
doaj
Euglycemia despite a sodium glucose co-transporter 2 inhibitor overdose [PDF]
World Journal of Emergency Medicine, 2022 Muhammad Akbar, Baig, Joshua, Nogar
openaire +2 more sources
Sodium–glucose co-transporter 2 inhibitors in heart failure
European Heart Journal - Cardiovascular Pharmacotherapy, 2021 Giuseppe M C Rosano +2 more
openaire +2 more sources
Sodium–glucose co‐transporter 2 inhibitors and acute heart failure [PDF]
European Journal of Heart Failure, 2020 Groenewegen, Amy, Rutten, Frans H
openaire +3 more sources
Brief Report: Use and Side Effects of Sodium-Glucose Transporter 2 Inhibitors Among US People With HIV With Clinical Indications. [PDF]
J Acquir Immune Defic Syndr, 2023 Sise ME +8 more
europepmc +1 more source
Sodium-glucose transporter 2 inhibitors may improve the prognosis of acute heart failure by correcting hypocapnia. [PDF]
ESC Heart Fail, 2023 Tang WJ, Yu M.
europepmc +1 more source
Patient considerations in the management of type 2 diabetes – critical appraisal of dapagliflozin
Patient Preference and Adherence, 2014 Marissa C Salvo,1 Amie D Brooks,2 Stacey M Thacker3 1Department of Pharmacy Practice, University of Connecticut School of Pharmacy, Storrs, CT, 2Department of Pharmacy Practice, St Louis College of Pharmacy, St Louis, MO, 3Department of Pharmacy Practice,
Salvo MC, Brooks AD, Thacker SM
doaj
Effect of sodium-glucose transporter 2 inhibitors on sarcopenia in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. [PDF]
Front Endocrinol (Lausanne), 2023 Zhang S, Qi Z, Wang Y, Song D, Zhu D.
europepmc +1 more source